Comparative Pharmacology
Head-to-head clinical analysis: DDAVP NEEDS NO REFRIGERATION versus DESMODA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DDAVP NEEDS NO REFRIGERATION versus DESMODA.
DDAVP (NEEDS NO REFRIGERATION) vs DESMODA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desmopressin is a synthetic analogue of vasopressin (antidiuretic hormone) that acts on V2 receptors in renal collecting ducts to increase water reabsorption and concentrate urine. It also raises plasma levels of factor VIII and von Willebrand factor via V2 receptor activation on endothelial cells.
Desmopressin is a synthetic analogue of vasopressin (antidiuretic hormone, ADH) that acts on V2 receptors in renal collecting ducts, increasing water reabsorption and reducing urine output. It also raises plasma levels of factor VIII and von Willebrand factor via V2 receptor stimulation on endothelial cells.
1-2 mg orally twice daily for central diabetes insipidus; intranasal 10-40 mcg/day in 1-3 divided doses; IV/SC 0.5-2 mcg/day in divided doses for diabetes insipidus.
10 mg orally once daily
None Documented
None Documented
Terminal elimination half-life is 1.5-3 hours for intravenous and oral routes; increased to 3-5 hours in patients with renal impairment.
Terminal half-life: 8-12 hours; extended in renal impairment (up to 24 hours).
Primarily renal (approximately 60-70% excreted unchanged in urine); minimal biliary/fecal elimination (<5%).
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites.
Category C
Category C
Antidiuretic Hormone Analog
Antidiuretic Hormone Analog